VYNE
VYNE Therapeutics Inc.
Key Financials
Net Income
$-26483000
↑ 33.5%
EPS (Diluted)
$-0.62
↑ 33.3%
Revenue
$570000
↑ 13.8%
Total Assets
$30.2M
↓ 54.9%
Total Liabilities
$2.4M
↓ 83.8%
Cash & Equivalents
$24.0M
↑ 20.6%
Operating Income
$-29749000
↑ 31.8%
Long-term Debt
$0.00
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| 4 | 7/2/2026 | View on SEC |
| ARS | 6/16/2026 | View on SEC |
| EFFECT | 6/15/2026 | View on SEC |
| 424B3 | 6/15/2026 | View on SEC |
| SCHEDULE 13G | 6/15/2026 | View on SEC |
| S-4/A | 6/3/2026 | View on SEC |
| 4 | 6/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | VYNE |
| Company Name | VYNE Therapeutics Inc. |
| CIK | 1566044 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 800-775-7936 |